**Amendments to the Claims:**

1. (original) A method of treating a disease treatable by the inhibition of the glycine transporter 2 (GlyT2) by administering a therapeutically effective amount of a compound of Formula I:




Formula I

where:

n is 0, 1, 2 or 3;

each R is independently halogen, hydroxy, lower alkyl optionally substituted with halogen, or lower alkoxy optionally substituted with halogen;

X is O, S or N—R′ (where R′ is lower alkyl, aryl, heteroaryl, aryl-lower alkylene or heteroaryl-lower alkylene);

Q may be absent or present, and when present is represented by the formula:




in which n, R and X are as defined above;

when Q is present, W is a lower alkylene, and

when Q is absent, W is optionally substituted lower alkyl, optionally substituted aryl, optionally substituted heteroaryl, (optionally substituted aryl)—X—$CH_2$— or (optionally substituted heteroaryl)—X—$CH_2$— in which X is as defined above,

or a pharmaceutically acceptable salt thereof.

2. (original) The method of Claim 1 where the disease is a nervous disorder.

3. (original) The method of Claim 1 where the disease is a muscular disorder.

4. (original) The method of Claim 1 wherein the disease is a disorder selected from the group consisting of psychoses, pain, epilepsy, neurodegenerative diseases, stroke, head trauma, multiple sclerosis, spasticity and myoclonus.

5. (original) The method of Claim 1 where X is N—R′ in which R′ is methyl, ethyl, phenyl, or benzyl, n is 0, 1 or 2, R is chlorine or methyl, Q is absent, and W is aryl, optionally substituted heteroaryl or (optionally substituted heteroaryl)—X—$CH_2$—.

6. (original) The method of Claim 5 where the compound is selected from
3-[(2,6-dichlorophenyl)methylthio]-5-(thien-2-ylthiomethyl)-4-methyl-1,2,4-triazole,
3-benzylthio-5-(thien-2-ylthiomethyl)-4-methyl-1,2,4-triazole,
3-(4-methylbenzylthio)-5-(thien-2-ylthiomethyl)-4-methyl-1,2,4-triazole,
3-[(2,6-dichlorophenyl)methylthio]-5-(thien-2-ylthiomethyl)-4-ethyl-1,3,4-triazole,
3-benzylthio-5-(2-ethyl-5-methyl-3-diazolyl)-4-phenyl-1,2,4-triazole, and
3-[(2,6-dichlorophenyl)methylthio]-5-phenyl-4-benzyl-1,3,4-triazole.

7. (original) The method of Claim 1 where X is S, n is 0, 1 or 2, R is chlorine, Q is absent, and W is aryl or heteroaryl.

8. (original) The method of Claim 7 where the compound is selected from
2-[(2,6-dichlorophenyl)methylthio]-5-(pyrazin-2-yl)-1,3,4-thiadiazole,
2-(benzylthio)-5-phenyl-1,3,4-thiadiazole,
2-(benzylthio)-5-(pyridin-3-yl)-1,3,4-thiadiazole,
2-[(2,6-dichlorophenyl)methylthio]-5-phenyl-1,3,4-thiadiazole, and
2-(benzylthio)-5-(pyrazin-2-yl)-1,3,4-thiadiazole.

9. (original) The method of Claim 1 where the compound is 2,2′-(1,4-butanediyl)-bis[5-(benzylthio)-1,3,4-oxadiazole].

10. – 28. (canceled)